An observational study in Biliary Tract Cancer, sponsored by Eisai Co., Ltd.. Recruiting at 1 site in Japan. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Eisai Co., Ltd. · Observational
The primary purpose of this study is to investigate the safety of Tasfygo.
519 studies on the registry are indexed under Biliary Tract Neoplasms; 199 are open to participants now.
This study's planned enrollment of 60 is below the median of 160 across 73 observational studies indexed under Biliary Tract Neoplasms.
Browse Biliary Tract Neoplasms studies →Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Participants with FGFR2 fusion positive unresectable biliary tract cancer with prior chemotherapy who will receive Tasfygo tablet as per daily practice and package insert will be enrolled.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1. Participants with unresectable biliary tract cancer with FGFR2 fusion gene positivity who are naïve to Tasfygo tablet and progressed after chemotherapy.
Exclusion Criteria:
Not applicable.
Other: No Intervention
This is a non-interventional study.
Number of Participants With Adverse Drug Reactions
Time frame: Up to 1 year
Percentage of Participants With Best Overall Response (BOR) Based on Physician's Assessment
Time frame: Up to 1 year
Plan to share: Yes — Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.